Literature DB >> 34050265

Advances in PSMA-targeted therapy for prostate cancer.

Fujin Wang1,2, Zhifeng Li1, Xiaoqian Feng1,2, Dazhuang Yang1, Mei Lin3.   

Abstract

Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein located on the cell membrane, is specifically and highly expressed in prostate cancer (PCa). Besides, its expression level is related to tumor invasiveness. As a molecular target of PCa, PSMA has been extensively studied in the past two decades. Currently, a great deal of evidence suggests that significant progresses have been made in the PSMA-targeted therapy of PCa. Herein, different PSMA-targeted therapies for PCa are reviewed, including radioligand therapy (177Lu-PSMA-RLT, 225Ac-PSMA-RLT), antibody-drug conjugates (MLN2704, PSMA-MMAE, MEDI3726), cellular immunotherapy (CAR-T, CAR/NK-92, PSMA-targeted BiTE), photodynamic therapy, imaging-guided surgery (radionuclide-guided surgery, fluorescence-guided surgery, multimodal imaging-guided surgery), and ultrasound-mediated nanobubble destruction.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34050265     DOI： 10.1038/s41391-021-00394-5

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


  83 in total

Review 1.  Current therapeutic options in metastatic castration-resistant prostate cancer.

Authors:  Gianluca Ingrosso; Beatrice Detti; Daniele Scartoni; Andrea Lancia; Irene Giacomelli; Muhammed Baki; Giulio Carta; Lorenzo Livi; Riccardo Santoni
Journal:  Semin Oncol       Date:  2018-10-30       Impact factor: 4.929

2.  An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin.

Authors:  Ahmad Fawzi Hussain; Mehmet Kemal Tur; Stefan Barth
Journal:  Nucleic Acid Ther       Date:  2013-04-01       Impact factor: 5.486

Review 3.  Targeted prodrug approaches for hormone refractory prostate cancer.

Authors:  Herve Aloysius; Longqin Hu
Journal:  Med Res Rev       Date:  2014-12-22       Impact factor: 12.944

Review 4.  Current progress of aptamer-based molecular imaging.

Authors:  Andrew Z Wang; Omid C Farokhzad
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

5.  Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

Authors:  Neil H Bander; Edouard J Trabulsi; Lale Kostakoglu; Daniel Yao; Shankar Vallabhajosula; Peter Smith-Jones; Maureen A Joyce; Matthew Milowsky; David M Nanus; Stanley J Goldsmith
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

Review 6.  New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.

Authors:  Alessia Cimadamore; Monica Cheng; Matteo Santoni; Antonio Lopez-Beltran; Nicola Battelli; Francesco Massari; Andrea B Galosi; Marina Scarpelli; Rodolfo Montironi
Journal:  Front Oncol       Date:  2018-12-21       Impact factor: 6.244

7.  Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis.

Authors:  Jianjian Xiang; Huaqing Yan; Jiangfeng Li; Xiao Wang; Hong Chen; Xiangyi Zheng
Journal:  World J Surg Oncol       Date:  2019-02-13       Impact factor: 2.754

8.  Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.

Authors:  Sara Pastorino; Mattia Riondato; Licia Uccelli; Giampiero Giovacchini; Elisabetta Giovannini; Valerio Duce; Andrea Ciarmiello
Journal:  Curr Radiopharm       Date:  2020

9.  Expression of prostate-specific membrane antigen in normal and malignant human tissues.

Authors:  Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282
View more
  4 in total

Review 1.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

2.  Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake.

Authors:  Falguni Basuli; Tim E Phelps; Xiang Zhang; Carolyn C Woodroofe; Jyoti Roy; Peter L Choyke; Rolf E Swenson; Elaine M Jagoda
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-13

Review 3.  Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.

Authors:  Ha Gyeong Shin; Ha Rim Yang; Aerin Yoon; Sukmook Lee
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

Review 4.  Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.

Authors:  Filipa Amaro; Márcia Carvalho; Maria de Lourdes Bastos; Paula Guedes de Pinho; Joana Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.